Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis
Clinical Gastroenterology and Hepatology · 2026-09 · 24 (9) · 2539-2550
DOI: 10.1016/j.cgh.2026.01.017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-09. Verfasst von Giuseppe Privitera und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Milan, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Ustekinumab, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND & AIMS: With the advent of agents targeting distinct inflammatory pathways, therapeutic sequencing after anti-tumor necrosis factor alpha (TNF-α) failure in ulcerative colitis (UC) represents a major challenge. We compared the real-world effectiveness and safety of vedolizumab, ustekinumab, and Janus kinase inhibitors (JAKis) in anti-TNF-α-exposed patients. METHODS: In this retrospective, multicenter European study, adults with UC initiating second-line vedolizumab, ustekinumab, or a JAKi after anti-TNF-α were evaluated. Baseline confounding was addressed by applying energy balancing weights (EBWs). Effectiveness outcomes included probability of steroid-free clinical remission (SFCR) and biochemical SFCR at 12 months, analyzed using EBW-weighted Royston-Parmar survival models to derive adjusted time-averaged hazard ratios (aHRs). Adverse event (AE) rates were compared using EBW-weighted Poisson regression. RESULTS: A total of 596 patients were included (301 vedolizumab, 149 ustekinumab, 146 JAKi); 54.7% were male, with a mean age of 43.9 ± 15.5 years. Clinical activity, endoscopic scores, and biomarker levels were broadly comparable across treatment groups. Infliximab was the most common prior anti-TNF-α (74.8%), and secondary failure was the predominant discontinuation reason (47.3%). Compared with vedolizumab, both ustekinumab and JAKi showed significantly higher probability of SFCR (aHR, 1.54; 95% confidence interval [CI], 1.09-2.07; and aHR, 1.66; 95% CI, 1.07-2.53, respectively) and biochemical SFCR (aHR, 2.26; 95% CI, 1.48-3.28 and 3.37; 95% CI, 2.01-5.36, respectively) at 12 months, with no differences between them. JAKi recipients experienced an approximately 4-fold higher incidence of AEs, compared with both vedolizumab and ustekinumab, with no differences between ustekinumab and vedolizumab. CONCLUSIONS: Ustekinumab and JAKi were more effective than vedolizumab in inducing steroid-free and biochemical remission following anti-TNF-α failure. Safety concerns with JAKi warrant careful patient selection in clinical practice. CLINICALTRIALS: gov, Number: NCT06691061.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy; IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy; IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
- Department of Gastroenterology, São João Hospital University Centre, Porto, Portugal.
- CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Zitieren
APA
Privitera, G., Bezzio, C., Figlioli, G., D'Amico, F., Mendes, J., Varca, S., Zingone, F., Rodriguez-Lago, I., Onali, S., Caprioli, F. A., Chaparro, M., Barreiro-de-Acosta, M., Karmiris, K., Degabli, N. T., Dar, L., Pastorelli, L., Gutiérrez, A., Orlando, A., Zabana, Y., …, & PODIUM Study Group (2026). Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 24(9), 2539-2550. https://doi.org/10.1016/j.cgh.2026.01.017
Vancouver
Privitera G, Bezzio C, Figlioli G, D'Amico F, Mendes J, Varca S, et al. Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2026;24(9):2539-2550. doi:10.1016/j.cgh.2026.01.017
BibTeX
@article{Privitera2026,
author = {Privitera, Giuseppe and Bezzio, Cristina and Figlioli, Gisella and D'Amico, Ferdinando and Mendes, Joao and Varca, Simone and Zingone, Fabiana and Rodriguez-Lago, Iago and Onali, Sara and Caprioli, Flavio A and Chaparro, María and Barreiro-de-Acosta, Manuel and Karmiris, Konstantinos and Degabli, Natalie Tamir and Dar, Lior and Pastorelli, Luca and Gutiérrez, Ana and Orlando, Ambrogio and Zabana, Yamile and Saibeni, Simone and Piovani, Daniele and Savarino, Edoardo V and Pugliese, Daniela and Magro, Fernando and Danese, Silvio and Armuzzi, Alessandro and PODIUM Study Group, PODIUM Study Group},
title = {Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {9},
pages = {2539--2550},
doi = {10.1016/j.cgh.2026.01.017}
}
EUVIMED